Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)

被引:26
|
作者
Palte, Rachel L. [1 ]
Schneider, Sebastian E. [1 ]
Altman, Michael D. [1 ]
Hayes, Robert P. [2 ]
Kawamura, Shuhei [1 ]
Lacey, Brian M. [1 ]
Mansueto, My Sam [1 ]
Reutershan, Michael [1 ]
Siliphaivanh, Phieng [1 ]
Sondey, Christopher [1 ]
Xu, Haiyan [1 ]
Xu, Zangwei [1 ]
Ye, Yingchun [1 ]
Machacek, Michelle R. [1 ]
机构
[1] Merck & Co Inc, Computat & Struct Chem, Boston, MA 02115 USA
[2] Computat & Struct Chem, West Point, PA 19486 USA
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 09期
关键词
PRMT5; allosteric inhibition; methyltransferase; peptide competitive; SAM competitive; crystal structure; SELECTIVE INHIBITOR; METHYLATION; POTENT; DISCOVERY; DELETION; HISTONE;
D O I
10.1021/acsmedchemlett.9b00525
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Protein arginine methyltransferase 5 (PRMT5) belongs to a family of enzymes that regulate the posttranslational modification of histones and other proteins via methylation of arginine. Methylation of histones is linked to an increase in transcription and regulates a manifold of functions such as signal transduction and transcriptional regulation. PRMT5 has been shown to be upregulated in the tumor environment of several cancer types, and the inhibition of PRMT5 activity was identified as a potential way to reduce tumor growth. Previously, four different modes of PRMT5 inhibition were known-competing (covalently or non-covalently) with the essential cofactor Sadenosyl methionine (SAM), blocking the substrate binding pocket, or blocking both simultaneously. Herein we describe an unprecedented conformation of PRMT5 in which the formation of an allosteric binding pocket abrogates the enzyme's canonical binding site and present the discovery of potent small molecule allosteric PRMT5 inhibitors.
引用
收藏
页码:1688 / 1693
页数:6
相关论文
共 50 条
  • [21] Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors
    Zhu, Kongkai
    Song, Jia-Li
    Tao, Hong-Rui
    Cheng, Zhi-Qiang
    Jiang, Cheng-Shi
    Zhang, Hua
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (23-24) : 3693 - 3699
  • [22] In silico analysis of marine natural product for protein arginine methyltransferase 5(PRMT5) inhibitors based on pharmacophore and molecular docking
    Luo, Lianxiang
    Tan, Huiting
    Liao, Yinglin
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2023, 41 (22) : 13180 - 13197
  • [23] Protein Arginine Methyltransferase 5 (Prmt5) Is Required for Germ Cell Survival During Mouse Embryonic Development
    Wang, Yanbo
    Li, Qiuling
    Liu, Chunyi
    Han, Feng
    Chen, Min
    Zhang, Lianjun
    Cui, Xiuhong
    Qin, Yan
    Bao, Shilai
    Gao, Fei
    BIOLOGY OF REPRODUCTION, 2015, 92 (04)
  • [24] LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity
    Bonday, Zahid Q.
    Cortez, Guillermo S.
    Grogan, Michael J.
    Antonysamy, Stephen
    Weichert, Ken
    Bocchinfuso, Wayne P.
    Li, Fengling
    Kennedy, Steven
    Li, Binghui
    Mader, Mary M.
    Arrowsmith, Cheryl H.
    Brown, Peter J.
    Eram, Mohammad S.
    Szewczyk, Magdalena M.
    Barsyte-Lovejoy, Dalia
    Vedadi, Masoud
    Guccione, Ernesto
    Campbell, Robert M.
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (07): : 612 - 617
  • [25] MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells
    Kryukov, Gregory V.
    Wilson, Frederick H.
    Ruth, Jason R.
    Paulk, Joshiawa
    Tsherniak, Aviad
    Marlow, Sara E.
    Vazquez, Francisca
    Weir, Barbara A.
    Fitzgerald, Mark E.
    Tanaka, Minoru
    Bielski, Craig M.
    Scott, Justin M.
    Dennis, Courtney
    Cowley, Glenn S.
    Boehm, Jesse S.
    Root, David E.
    Golub, Todd R.
    Clish, Clary B.
    Bradner, James E.
    Hahn, William C.
    Garraway, Levi A.
    SCIENCE, 2016, 351 (6278) : 1214 - 1218
  • [26] Type II protein arginine methyltransferase 5 (PRMT5) is required for circadian period determination in Arabidopsis thaliana
    Hong, Sunghyun
    Song, Hae-Ryong
    Lutz, Kerry
    Kerstetter, Randall A.
    Michael, Todd P.
    McClung, C. Robertson
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (49) : 21211 - 21216
  • [27] Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma
    Sloan, Shelby L.
    Renaldo, Kyle A.
    Long, Mackenzie
    Chung, Ji-Hyun
    Courtney, Lindsay E.
    Shilo, Konstantin
    Youssef, Youssef
    Schlotter, Sarah
    Brown, Fiona
    Klamer, Brett G.
    Zhang, Xiaoli
    Yilmaz, Ayse S.
    Ozer, Hatice G.
    Valli, Victor E.
    Vaddi, Kris
    Scherle, Peggy
    Alinari, Lapo
    Kisseberth, William C.
    Baiocchi, Robert A.
    PLOS ONE, 2021, 16 (05):
  • [28] The protein arginine methyltransferase PRMT5 promotes D2-like dopamine receptor signaling
    Likhite, Neah
    Jackson, Christopher A.
    Liang, Mao-Shih
    Krzyzanowski, Michelle C.
    Lei, Pedro
    Wood, Jordan F.
    Birkaya, Barbara
    Michaels, Kerry L.
    Andreadis, Stelios T.
    Clark, Stewart D.
    Yu, Michael C.
    Ferkey, Denise M.
    SCIENCE SIGNALING, 2015, 8 (402)
  • [29] Identification of protein arginine N-methyltransferase 5 (PRMT5) as a novel interacting protein with the tumor suppressor protein RASSF1A
    Sakai, Nobuya
    Saito, Yumiko
    Fujiwara, Yoko
    Shiraki, Takashi
    Imanishi, Yorihisa
    Koshimizu, Taka-aki
    Shibata, Katsushi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 467 (04) : 778 - 784
  • [30] The arginine methyltransferase PRMT5 regulates CIITA-dependent MHC II transcription
    Fan, Zhiwen
    Kong, Xiaocen
    Xia, Jun
    Wu, Xiaoyan
    Li, He
    Xu, Huihui
    Fang, Mingming
    Xu, Yong
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2016, 1859 (05): : 687 - 696